Vertex Pharmaceuticals
$504.73Change from previous close: −0.40%Absolute change: −$2.01
At a glance
- Revenue growth
- +8.90%
- 2025 vs 2024
- Net margin
- 32.9%
- 2024: -4.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 25,643 | 22,533 | 22,730 | 18,151 | 13,433 | 11,752 | 8,318 | 6,246 | 3,546 | 2,897 |
| Current assets | 11,201 | 9,596 | 14,144 | 13,235 | 9,561 | 8,133 | 4,823 | 3,843 | 2,649 | 1,832 |
| Cash and equivalents | 5,085 | 4,570 | 10,369 | 10,504 | 6,795 | 5,988 | 3,109 | 2,650 | 1,665 | 1,184 |
| Short-term investments | 1,523 | 1,546 | 849 | 275 | 730 | 671 | 699 | 518 | 423 | 251 |
| Receivables | 2,053 | 1,609 | 1,563 | 1,442 | 1,137 | 885 | 634 | 410 | 384 | 220 |
| Inventory | 1,687 | 1,205 | 739 | 461 | 353 | 281 | 168 | 124 | 112 | 77.6 |
| Net property, plant and equipment | 3,083 | 2,585 | 1,453 | 1,456 | 1,424 | 1,284 | 833 | 812 | 789 | 698 |
| Goodwill | 1,088 | 1,088 | 1,088 | 1,088 | 1,002 | 1,002 | 1,002 | 50.4 | 50.4 | 50.4 |
| Other intangible assets | 424 | 826 | 840 | 604 | 400 | 400 | 400 | — | 29.0 | 284 |
| Long-term investments | 5,794 | 5,173 | 2,498 | 112 | — | — | — | — | — | 20.3 |
| Current liabilities | 3,861 | 3,565 | 3,547 | 2,742 | 2,142 | 1,878 | 1,335 | 1,120 | 807 | 793 |
| Accounts payable | 462 | 413 | 365 | 304 | 195 | 155 | 87.6 | 111 | 74.0 | 61.5 |
| Total debt | 2,036 | 1,750 | 808 | 900 | 967 | 942 | 673 | 587 | 606 | 541 |
| Total liabilities | 6,977 | 6,124 | 5,150 | 4,238 | 3,333 | 3,065 | 2,233 | 1,811 | 1,504 | 1,559 |
| Total equity (incl. minority) | 18,666 | 16,410 | 17,580 | 13,913 | 10,100 | 8,687 | 6,085 | 4,435 | 2,042 | 1,338 |
| Retained earnings | 13,560 | 9,607 | 10,142 | 6,523 | 3,201 | 859 | -1,853 | -2,989 | -5,120 | -5,374 |
| Minority interest | — | — | — | — | — | — | — | — | 13.7 | 182 |